Respiratory fluoroquinolones monotherapy versus β-lactams plus macrolides combination therapy for non-ICU hospitalized community-acquired pneumonia patients: A meta-analysis

Chinese Journal of Evidence-Based Medicine

Volumn 15, Issue 7, 2015, Pages 824-832

  Fan, Hong ^a   Liu, Si Tong ^a   Tong, Xiang ^a   Peng, Shi Feng ^a   Ma, Yao ^b   Yan, Zhi Peng ^a   Yang, Xin ^a   Du, Liang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Community acquired pneumonia; Fluoroquinolones; Macrolides; Meta analysis; Randomized controlled trial; Systematic review; Lactams

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; QUINOLONE DERIVATIVE;

BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84938372093     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: 10.7507/1672-2531.20150137     Document Type: Review

References (24)

1. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med, 2014, 371(17): 1619-1628.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2): S27-72.
3. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax, 2009, 64(Suppl 3): iii1-55.
4. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect, 2011, 17(Suppl 6): E1-59.
5. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ, 2008, 179(12): 1269-1277.
6. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis, 2012, 55(3): 371-380.
7. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother, 2002, 36(12): 1938-1943.
8. An MM, Zou Z, Shen H, et al. Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents, 2010, 36(1): 58-65.
9. Higgins J, Altman D. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org.
10. Erard V, Lamy O, Bochud PY, et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 2004, 23(2): 82-88.
11. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (iv) and oral moxifloxacin compared with sequential iv and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother, 2002, 46(6): 1746-1754.
12. Fogarty C, Siami G, Kohler R,et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis, 2004, 38(Suppl 1): S16-S23.
13. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther, 2002, 24(8): 1292-1308.
14. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential iv to po moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial iv therapy. J Emerg Med, 2004, 27(4): 395-405.
15. Lin T, Lin S, Chen H, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J, 2007, 30(4): 321.
16. Lode H, File TM, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther, 2002, 24(11): 1915-1936.
17. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis, 2005, 24(6): 367-376.
18. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med, 2015, 372(14): 1312-1323.
19. Torres A, Muir J, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J, 2003, 21(1): 135-143.
20. Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis, 2005, 41(12): 1697-1705.
21. Xu S, Xiong S, Xu Y, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci, 2006, 26(4): 421-424.
22. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med, 2004, 3(5): 329-336.
23. Guidance for Industry-Draft. Developing Antimicrobial Drugs- General Considerations for Clinical Trials. July 1998. Available at: http://www.fda.govlcderlguidancei2580dft.pdf.
24. Skalsky K, Yahav D, Lador A, et al. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect, 2013, 19(4): 370-378.